Clinical trials
Colorectal Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting colorectal cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04861415Recruiting
Testing a shorter radiation plan versus standard prostate radiation
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
Toronto, OntarioAges 18 years+ - NCT04861194Recruiting
Test treatment plans to preserve erections during prostate radiation
This trial studies ways to help preserve erectile function while you receive radiation treatment for prostate cancer. It may help by aiming to protect erections, especially for people at low to intermediate risk.
Utrecht, UtrechtAges 18 years+ - NCT04868162RecruitingPhase 2
MRG003 for head and neck cancer after prior treatments
This trial tests MRG003, a cancer medicine, in people with recurrent or metastatic squamous cell carcinoma of the head and neck who have already tried and had trouble with standard treatments like platinum and anti–PD-1 therapy. It looks at whether the treatment can shrink the cancer and how safe it is.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04871399Recruiting
Right colon cancer surgery with more thorough tissue removal
This trial compares a more complete surgery (removing the right colon and surrounding tissue more thoroughly) versus the usual right-colon surgery. It aims to see if the more thorough approach improves outcomes for people with non-metastatic right colon cancer.
Grosseto, ArezzoAges 18–85 - NCT04874064Recruiting
AI blood tests for triple-negative breast cancer after treatment
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
London, OntarioAges 18 years+ - NCT04894370RecruitingPhase 2
Trial tests immunotherapy plus chemotherapy and radiation for anal cancer
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
BesançonAges 18 years+ - NCT04903119RecruitingPhase 1
Targeted drugs for metastatic melanoma with a BRAF mutation
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
Iowa City, IowaAges 18 years+ - NCT04914663Recruiting
Exercise program during breast cancer chemotherapy
This study tests whether supervised exercise during chemotherapy is safe and helpful for people with early-stage breast cancer. It may support physical function and well-being while you are receiving cancer treatment.
Gainesville, FloridaAges 18–85 - NCT04921137RecruitingPhase 4
Testing benefits and side effects of hormone therapy in older breast cancer patients
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
Edmonton, AlbertaAges 70 years+ - NCT04925856Recruiting
Monitoring the immune system during breast cancer drug treatment
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
BesançonAges 18–85 - NCT07699328RecruitingPhase 1/Phase 2
Study of VRN110755 for EGFR-mutant lung cancer
This trial tests a new oral targeted therapy (VRN110755) for people with EGFR-mutant lung cancer. It is for those whose cancer has advanced or spread, and who either have not been treated yet or who stopped responding to previous EGFR pills.
Bedford Park, South AustraliaAges 18 years+ - NCT06976944RecruitingPhase 2
Pembrolizumab, Paclitaxel, and Bevacizumab for Triple-Negative Breast Cancer
This trial tests a combination of the immunotherapy drug pembrolizumab, the chemotherapy paclitaxel, and possibly the targeted drug bevacizumab for people with triple-negative breast cancer that has returned after treatment. It aims to see if adding bevacizumab improves outcomes for patients whose tumors are PD-L1 positive.
Nagoya, Aichi-kenAges 18 years+ - NCT07697859Recruiting
Immunotherapy with local treatment for limited spread esophageal cancer
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07697937RecruitingPhase 2
YH02 injection for advanced solid tumors that didn't respond to treatment
This trial tests a new injection, YH02, directly into tumors for people with advanced solid tumors (like head and neck, breast, or melanoma) that are no longer responding to standard treatments. The goal is to see if it can shrink tumors or slow disease progression.
TianjinAges 18 years+ - NCT07238894Recruiting
Freezing and heating breast cancer without surgery
This study tests a combination of freezing and heating (cryoablation and thermal ablation) to treat breast cancer in patients who cannot have surgery. It may help shrink or control tumors while avoiding general anesthesia.
BeijingAges 18–80 - NCT04974671RecruitingPhase 2
SBRT radiation for limited cancer growth on immunotherapy
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
New Haven, ConnecticutAges 18 years+ - NCT05000697Recruiting
Watch-and-wait or chemo after rectal cancer radiation
This trial studies people with early-to-mid stage distal rectal cancer who may get radiation and chemotherapy, with an option that may include an extra drug (oxaliplatin). It also tests whether some people can safely follow a “watch and wait” plan instead of immediate additional treatment, aiming to reduce overtreatment while keeping cancer control.
Buenos AiresAges 18 years+ - NCT05033691Recruiting
Osimertinib plus early brain radiation versus osimertinib alone
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
JerusalemAges 18–120 - NCT05037279RecruitingPhase 3
Testing BCG treatment for bladder cancer after full tumor removal
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Vancouver, British ColumbiaAges 18 years+ - NCT05038332RecruitingPhase 2
Testing two types of radiation after prostate surgery
This Phase 2 study compares two schedules of radiation treatment after prostate surgery in men whose PSA starts rising again. It aims to see which radiation approach works well while tracking quality of life and safety.
Ann Arbor, MichiganAges 18 years+ - NCT05052671Recruiting
Blood test for residual cancer in resectable pancreatic cancer
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Oklahoma City, OklahomaAges 18–99 - NCT05058183Recruiting
Testing shorter chemotherapy for early HER2 or triple‑negative breast cancer
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
LondonAges 18 years+ - NCT05074290RecruitingPhase 1/Phase 2
Testing safety and drug levels of a breast cancer drug plus taxane
This early-phase study tests how epidiferphane works in the body and whether it is safe when combined with standard chemotherapy “taxanes” (paclitaxel or docetaxel) for breast cancer. If you qualify, you may be starting a new taxane treatment plan at the study site, and you would be followed closely for side effects and drug levels.
Gainesville, FloridaAges 18–99 - NCT05076682RecruitingPhase 2
Study for hard-to-treat triple-negative breast cancer that keeps growing
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
ShanghaiAges 18–70
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,580 recruiting colorectal cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced Colorectal Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
- Metastatic Colorectal Cancer (CRC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.